MAPK-targeted therapies, whether employed as monotherapy or combination therapy of BRAF and MEK inhibitors, have significantly increased the overall survival rate in metastatic melanoma cases; nevertheless, acquired resistance almost invariably emerges irrespective of the specific agents used or their combinations [39]. The gene discussed is MAP2K7; the disease is metastatic melanoma.